Marksans Pharma Ltd. reported a stable performance in Q3 FY26, with operating revenue growing 10.6% YoY. Margins expanded sequentially, driven by raw material costs and currency movements. The company strengthened its global footprint with new subsidiaries in Europe and Canada. 9M FY26 reflects a soft Q1, followed by a healthy growth trajectory in Q2 and Q3.
Financial Performance
In Q3 FY26, Marksans Pharma delivered a resilient performance, achieving revenue growth of 10.6% YoY. This was supported by steady execution across key markets and improved seasonal demand. Margins expanded due to favorable raw material costs and currency movements. During the quarter, the company strengthened its global presence by establishing new subsidiaries in Europe and Canada.
Key Financial Highlights for Q3 FY26:
- Operating Revenue: ₹754 cr
- EBITDA: ₹161 cr
- EBITDA Margin: 21.3%
- PAT: ₹114 cr
Key Financial Highlights for 9M FY26:
- Operating Revenue: ₹2,095 cr
- EBITDA: ₹405 cr
- EBITDA Margin: 19.4%
- PAT: ₹271 cr
Segmental Performance
The company’s revenue streams can be broken down as follows:
- US & North America: ₹412.4 cr
- UK & Europe: ₹258.2 cr
- Australia & New Zealand: ₹61.4 cr
- Rest of World: ₹22.4 cr
Strategic Initiatives
Marksans Pharma is focused on store-brand OTC segments, innovation, and expanding capacity. The company is also committed to sustainable and responsible growth. Key strategies include expanding within proven OTC demand areas, focusing on R&D for a strong product pipeline, and expanding capacity at the acquired unit in Goa.
Future Outlook
Marksans aims for high growth in revenues and margin, targeting revenue of ₹3,000 cr in a year. The company plans to double revenue in the US and North America, becoming a top OTC company, and to rank among the top Indian pharmaceutical firms in the UK.
Source: BSE
